Form 4: Amphastar Director Sells Shares After Option Exercise
Insider Transaction Report
Amphastar Pharmaceuticals Director Floyd F. Petersen exercised stock options and subsequently sold 16,679 shares of common stock.
Summary
- Floyd F. Petersen, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), reported transactions on November 13, 2025.
- Petersen acquired 16,679 shares of common stock by exercising stock options at a price of $16.69 per share.
- Immediately following the option exercise, Petersen sold all 16,679 shares of common stock on the open market.
- The shares were sold at a weighted average price of $26.4906 per share, with individual sales ranging from $26.43 to $26.57.
- The transactions were made pursuant to a Rule 10b5-1(c) plan.
- After these transactions, Petersen directly beneficially owns 75,531 shares of Amphastar Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The filing is a routine insider transaction report (Form 4) detailing the exercise of stock options and subsequent sale of shares, often pre-planned under a 10b5-1 plan. It does not inherently convey positive or negative sentiment about the company's future prospects.
Positives
- The Director realized a profit of $9.8006 per share from the exercise and sale, totaling approximately $163,460.80, indicating personal financial gain from company equity.
Negatives
- The Director reduced their direct beneficial ownership of common stock by 16,679 shares following the sale.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | Transaction made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan to avoid accusations of trading on material non-public information. | 11/13/2025 | Enhances transparency and reduces potential for insider trading concerns by demonstrating a pre-planned, non-discretionary transaction. |
Stakeholder Impact
- Shareholders: The transaction represents a director's exercise of options and subsequent sale of shares, which is a routine event. The reduction in direct ownership is minor in the context of overall company equity.
Key Dates
| Date | Description |
|---|---|
| 11/13/2025 | Date of reported transactions (option exercise and share sale) |
| 11/17/2025 | Date the Form 4 was signed by power of attorney |
Keywords
Amphastar Pharmaceuticals, AMPH, Insider Transaction, Form 4, Stock Options, Director, Share Sale, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.